Free Trial

Novartis (NVS) to Release Quarterly Earnings on Thursday

Novartis logo with Medical background

Novartis (NYSE:NVS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 17th. Analysts expect Novartis to post earnings of $2.37 per share and revenue of $13.94 billion for the quarter.

Novartis (NYSE:NVS - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.12 by $0.16. Novartis had a net margin of 24.70% and a return on equity of 39.44%. The company had revenue of $13.23 billion for the quarter, compared to the consensus estimate of $12.92 billion. During the same quarter in the previous year, the company earned $1.80 EPS. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Novartis Stock Up 1.0%

Shares of NYSE:NVS opened at $122.95 on Thursday. Novartis has a 52 week low of $96.06 and a 52 week high of $124.45. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.61 and a current ratio of 0.79. The company's fifty day moving average is $115.63 and its 200-day moving average is $109.42. The company has a market capitalization of $259.72 billion, a PE ratio of 19.21, a P/E/G ratio of 1.67 and a beta of 0.59.

Hedge Funds Weigh In On Novartis

Large investors have recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after purchasing an additional 2,666 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Novartis during the 1st quarter worth approximately $1,764,000. Finally, AQR Capital Management LLC raised its stake in shares of Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company's stock worth $2,516,000 after purchasing an additional 11,444 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company's stock.

Analyst Upgrades and Downgrades

Separately, BNP Paribas raised Novartis to a "strong-buy" rating in a report on Tuesday, April 15th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $123.67.

Check Out Our Latest Analysis on Novartis

Novartis Company Profile

(Get Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Featured Stories

Earnings History for Novartis (NYSE:NVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novartis Right Now?

Before you consider Novartis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.

While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines